DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT07295223

GALACTUS

RecruitingPhase 3

Effect of Glp-1 and Antidiabetic sgLT2 Agents for myoCardial infarcTion and Ultrasensitive Inflammatory Surveillance (GALACTUS Trial)

GLP-1 and Antidiabetic SGLT2 Agents for Myocardial Infarction and Ultrasensitive Inflammatory Surveillance: An Open-Label Pilot Study

Asset

Semaglutide

GLP-1 agonist

Listed sites

1

Recruiting sites

1

Enrollment

44

estimated

Study population

Cardiovascular disease, Obesity / overweight, Type 2 diabetes

Key I/E criterion

•EF ≥50%

Primary endpoints

•Hs-CRP, change•Inflammatory markers (interleukin 6)

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07295223
Org study IDF-2024-1001-136

Timeline

Milestones

Study first posted2025-12-19actual
Study start2025-12-30actual
Last update posted2026-01-05actual
Primary completion2026-08estimated (month precision)
Study completion2026-09estimated (month precision)

Assets

Investigational agents

Semaglutide

Study populations

Who this study enrolls

Cardiovascular diseaseObesity / overweightType 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Criteria for the fourth definition of acute myocardial infarction with ST-segment elevation.
•Diagnosed with type 2 diabetes.
•Initial serum high-sensitivity CRP value > 2.0 mg/L.
•Clinically obese.
•LVEF >50%.

Exclusion criteria

•Patients who have recently received immunosuppressive therapy
•Patients with a history of ischemic heart disease
•Known allergy to any of the medications used
•Use of any of the study drugs more than 6 months prior to randomization
•Patients experiencing diabetic ketoacidosis
•Patients with hemodynamic instability (mean arterial pressure <60 mmHg while on vasopressors)
•Pregnant women
•Patients with a history or current diagnosis of cancer
•Patients with documented active infections, such as pneumonia or urinary tract infections
•Patients with pancreatitis

Endpoints (5)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Cardiometabolic biomarkers
3
Weight & body composition
1
Glycemic / diabetes
1

Weight & body composition

1 endpoint
Secondary/protocol endpoint

Epicardial fat

Time frame:24 weeks

Visceral fat, change

change from baseline, improvement

Glycemic / diabetes

1 endpoint
Secondary/protocol endpoint

Change in glucose and HbA1c

Time frame:24 weeks

change from baseline, improvement

Cardiometabolic biomarkers

3 endpoints
Primary/protocol endpoint

Inflammatory markers (high-sensitivity PCR)

Time frame:24 weeks.

hs-CRP, change

change from baseline, improvement

LOINC 30522-7

Primary/protocol endpoint

Inflammatory markers (interleukin 6)

Time frame:24 weeks

change from baseline, improvement

Secondary/protocol endpoint

LDL cholesterol

Time frame:24 weeks

LDL-C, change

change from baseline, improvement

LOINC 13457-7

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.